Abstract:It is well established that monoamines, such as serotonin (5-HT), noradrenaline, and dopamine, are fundamental in emotions and mood regulation. They also play a key role in the pathophysiology and treatment of mood disorders, such as unipolar and bipolar depression, as well as anxiety disorders, such as generalized anxiety, obsessive-compulsive, panic, and post-traumatic stress disorders [1]. We may underline three factors that are of critical importance for the proper understanding of the role of monoamines in mood disorders. The first one is the autoregulatory mechanism within the monoaminergic circuits [2]. The second one is the multiple crossinteraction between different monoamines [3]. The third factor is the crosstalk between monoamines and other bioactive molecules influencing mood regulation and mental functions in general. Examples of particularly important bioactive molecules are amino acid neurotransmitters, trace amines (biological amines biochemically related to the "classical" monoamines, but present in the brain in trace concentrations, such as tyramine, octopamine, and tryptamine), corticosteroids, adenosine, endogenous opioids, and cannabinoids (Fig 1).While the auto-and cross-regulatory mechanisms of the central monoaminergic systems have been extensively studied in the last decades, the crosstalk between monoamines and specific other biomolecules involved in mood regulation received lesser attention. This collection of articles was prepared in order to diminish this gap in knowledge and to stimulate future research in this direction.The task was completed thanks to the international team of researchers, coming from different parts of the world (Asia, America, Europe) and employment sectors (universities, public hospitals and research centers, and industrial enterprises). These researchers contributed their outstanding articles addressing the abovementioned points.Sha Zhao and colleagues from the Qingdao University, Qingdao, China, provided a review article on endocannabinoid-monoamine interactions, learning, and memory. Elad Lerer and co-authors from the Hadassah Medical Center, Jerusalem, Israel, contributed original research on the neurochemical mechanisms underlying putative beneficial effect of psychedelics in mental disorders. Daniela Jezova with Eliyahu Dremencov and their co-authors from the Biomedical Research Center and Centre of Biosciences, Slovak Academy of Sciences, Bratislava, Slovakia, shared with us an original research article on functional interactions between monoamines, glutamate, and endogenous opioids, focusing on prenatal effect of the ligands of opioid receptors on monoaminergic and glutamatergic transmission. Stephen Daniels and co-authors from the Institute of Mental Health Research, University of Ottawa, Ottawa, Canada, prepared an original research paper on glutamate-monoamine interactions and their role in the rapid antidepressant effect of ketamine. Hurmat Malik and co-contributors from the COMSATS University Islamabad, Islamabad, Pakistan, shared with us the results of their research on the interactions between monoamines, adenosine, microelements and steroids, with a practical focus on the putative anxiolytic and antidepressant-like effects of a natural element, diosgenin. Karolina Kolaczynska and Legend to the Figure Figure 1: Functional interactions between monoamines and other signaling biomolecules. VTA DA, ventral tegmental area dopamine neuron, LC NA, locus coeruleus noradrenaline neuron, TMN HA, tuberomammillary nucleus histamine neuron, DRN 5-HT, dorsal raphe nucleus serotonin (5-HT) neuron, ARN BEN, arcuate nucleus β-endorphin neuron, PFC GLU, prefrontal cortex glutamate neuron, A2A, adenosine-2A receptor, D2, dopamine-2 receptor, α1/2-alpha-1/2 adrenoceptor, H1/3histamine-1/3 receptor, 5-HT1A, serotonin-1A receptor, DOR-δ-opioid receptor, GR, glucocorticoid receptor, NMDA, N-methyl-D-aspartate glutamate receptor, CB1, cannabinoid-1 receptor, TAAR1, trace amine associated receptor 1, CS, corticosteroids, EC, endocannabinoids, +, stimulatory effect, -, inhibitory effect. According to [3; 4; 5; 6; 7; 8; 9].

The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs

Targeting Gap Junctions: New Insights into the Treatment of Major Depressive Disorder

Antidepressant activity: contribution of brain microdialysis in knock-out mice to the understanding of BDNF/5-HT transporter/5-HT autoreceptor interactions

Update on GPCR-based targets for the development of novel antidepressants

Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies

5-HT2A mediated plasticity as a target in major depression: a narrative review connecting the dots from neurobiology to cognition and psychology

Astroglial Connexin43 as a Potential Target for a Mood Stabiliser

Depression as a Glial-Based Synaptic Dysfunction

The brain galanin receptors: targets for novel antidepressant drugs

Editorial: New players on the monoaminergic field: relevance to the mental disorders

Novel insight into astrocyte-mediated gliotransmission modulates the synaptic plasticity in major depressive disorder

New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity

A brief history of the development of antidepressant drugs: From monoamines to glutamate.

Assessing the Neuronal Serotonergic Target-based Antidepressant Stratagem: Impact of In Vivo Interaction Studies and Knockout Models

The Association Between Antidepressant Effect of SSRIs and Astrocytes: Conceptual Overview and Meta‐analysis of the Literature

Antidepressants Impact Connexin 43 Channel Functions in Astrocytes

[Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders]

Signaling pathways involved in antidepressant-induced cell proliferation and synaptic plasticity.

Serotonin is a Common Thread Linking Different Classes of Antidepressants

The neuropharmacology of serotonin and noradrenaline in depression

Serotonin and beyond: therapeutics for major depression